Table 1.
Patient sociodemographic characteristics, habits, and disease/treatment characteristics (n=184)
| Characteristics | Number | % |
|---|---|---|
| Age groups (year) | ||
| 18–40 | 20 | 10.9 |
| 41–50 | 33 | 17.9 |
| 51–60 | 65 | 35.3 |
| 61 and over | 66 | 35.9 |
| Gender | ||
| Female | 105 | 57.1 |
| Male | 79 | 42.9 |
| Diagnosis | ||
| Lymphoma | 20 | 10.9 |
| Multiple myeloma | 19 | 10.3 |
| Breast Cancer | 46 | 25.0 |
| Lung Cancer | 25 | 13.6 |
| Colorectal Cancer | 42 | 22.8 |
| Over Cancer | 13 | 7.1 |
| Pancreatic Cancer | 6 | 3.3 |
| Other* | 13 | 7 |
| Clinical Stage | ||
| I | 20 | 10.9 |
| II | 69 | 37.5 |
| III | 53 | 28.8 |
| IV | 42 | 22.8 |
| Treatment Protocol | ||
| Paclitaxel, herceptin | 29 | 15.8 |
| Fluorouracil, calcium folinate, irinotecan, bevacizumab | 25 | 13.6 |
| Paclitaxel | 19 | 10.3 |
| Gemcitabine, cisplatin | 26 | 14.1 |
| Carboplatin, paclitaxel | 15 | 8.2 |
| Cyclophosphamide, bortezomib, dexamethasone | 11 | 6.0 |
| Fluorouracil, calcium folinate, oxaliplatin | 13 | 7.1 |
| Rituximab, cyclophosphamide, doxorubicin, vincristine, prednol | 12 | 6.5 |
| Doxorubicin, bleomycin, vinblastine, dacarbazine | 8 | 4.3 |
| Other** | 26 | 14.1 |
| Habits | ||
| Cigarette | ||
| Non-smoker | 96 | 52.2 |
| Former smoker | 76 | 41.3 |
| Smoker | 12 | 6.5 |
| Alcohol | ||
| Does not Drink | 166 | 90.2 |
| Used to Drink, but quitted | 18 | 9.8 |
| Oral Care | ||
| Brushing teeth | 98 | 53.3 |
| Rinsing mouth with water | 27 | 14.7 |
| Mouthwash | 19 | 10.3 |
| Brushing teeth+Mouthwash | 40 | 21.7 |
*
Malignant neoplasm of brain (n=3), prostate cancer (n=1), bladder cancer (n=2), testicular cancer (n=3), gastric cancer (n=2), and nasopharyngeal cancer (n=2).
**
Fluorouracil+calcium folinate (n=5), ifosfamide+gemcitabine+vinorelbine (n=4), irinotecan+cetuximab (n=4), gemcitabine+bevacizumab (n=3), cisplatin+docetaxel (n=2), docetaxel (n=2), bleomycin+etoposide+cisplatin (n=2), brentuximab+cyclophosphamide+procarbazine+prednisone (n=2), topotecan (n=1), and cisplatin+doxorubicin (n=1).